InterOcean Capital LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,952 shares of the biopharmaceutical company’s stock after selling 500 shares during the quarter. InterOcean Capital LLC’s holdings in Gilead Sciences were worth $594,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. TRUE Private Wealth Advisors bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $25,000. Pin Oak Investment Advisors Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at approximately $26,000. Baldwin Brothers Inc. MA lifted its stake in Gilead Sciences by 63.3% in the 1st quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 136 shares in the last quarter. IndexIQ Advisors LLC acquired a new position in Gilead Sciences during the 4th quarter worth approximately $28,000. Finally, TFO TDC LLC acquired a new position in Gilead Sciences during the 4th quarter worth approximately $29,000. Institutional investors own 77.34% of the company’s stock.
A number of analysts have recently commented on the stock. SVB Leerink boosted their price objective on shares of Gilead Sciences from $68.00 to $85.00 and gave the stock a “market perform” rating in a research report on Friday, May 1st. Bank of America increased their price objective on shares of Gilead Sciences from $70.00 to $72.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 5th. Barclays began coverage on Gilead Sciences in a research report on Thursday, February 27th. They issued an “underweight” rating and a $62.00 target price on the stock. Cowen reiterated a “buy” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Monday, April 13th. Finally, Raymond James downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating in a research note on Friday, May 1st. Seven research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $78.15.
In other Gilead Sciences news, Director John Francis Cogan sold 2,413 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $83.00, for a total transaction of $200,279.00. Following the transaction, the director now owns 57,273 shares in the company, valued at approximately $4,753,659. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Brett A. Pletcher sold 13,210 shares of Gilead Sciences stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total value of $1,046,628.30. Following the completion of the transaction, the executive vice president now directly owns 27,204 shares of the company’s stock, valued at $2,155,372.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,585 shares of company stock worth $4,671,283. 0.13% of the stock is owned by insiders.
Shares of NASDAQ GILD traded down $0.16 during trading hours on Friday, reaching $73.34. 6,157,451 shares of the stock were exchanged, compared to its average volume of 19,139,120. The firm has a market capitalization of $92.20 billion, a price-to-earnings ratio of 18.85, a P/E/G ratio of 3.14 and a beta of 0.72. The stock’s fifty day simple moving average is $77.78 and its 200 day simple moving average is $70.16. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.92 and a current ratio of 3.04. Gilead Sciences, Inc. has a 52 week low of $60.89 and a 52 week high of $85.97.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.68 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.11. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The firm had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same period in the prior year, the firm posted $1.67 EPS. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. Research analysts predict that Gilead Sciences, Inc. will post 6.34 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Friday, June 12th will be paid a $0.68 dividend. The ex-dividend date is Thursday, June 11th. This represents a $2.72 annualized dividend and a dividend yield of 3.71%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.30%.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: NASDAQ
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.